logo
logo
The Cooper Companies, Inc.

The Cooper Companies, Inc.

NASDAQ•COO
CEO: Mr. Albert G. White III
セクター: Healthcare
業種: Medical - Instruments & Supplies
上場日: 1983-01-21
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage to health care professionals and patients worldwide. It offers surgical and office products, including endosee endometrial imaging products, fetal pillow cephalic elevation devices for use in cesarean sections, illuminated speculum products, lone star retractor systems, loop electrosurgical excision procedure products, mara water ablation systems, paragard contraceptive IUDs, point-of-care, and uterine positioning products, as well as cryostorage, such as cord blood and cord tissue storage; fertility products and services, such as fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
連絡先情報
6101 Bollinger Canyon Road, Suite 500, San Ramon, CA, 94583, United States
925-460-3600
www.coopercos.com
時価総額
$16.50B
PER (TTM)
43.9
65.7
配当利回り
--
52週高値
$93.00
52週安値
$61.78
52週レンジ
68%
順位35Top 29.9%
4.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 4.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$1.07B+4.59%
直近4四半期の推移

EPS

$0.43-27.12%
直近4四半期の推移

フリーCF

$149.90M+0.00%
直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Consolidated Net Sales Growth Consolidated Net Sales reached $4.09B USD in fiscal 2025, showing a 5% increase compared to the prior year's $3.89B USD.
Operating Cash Flow Surge Cash provided by operating activities totaled $796.1M USD, marking a substantial 12.2% increase over the $709.3M USD generated in 2024.
CooperVision Sales Momentum CooperVision net sales grew 5% to $2.74B USD, primarily driven by strong market gains in silicone hydrogel contact lenses across regions.
CooperSurgical Acquisition Boost CooperSurgical net sales rose 5% to $1.35B USD, aided by increased Paragard sales and the recent acquisition of obp Surgical assets.

リスク要因

Macroeconomic Headwinds Persist Adverse global economic conditions, persistent inflation, and geopolitical instability continue to present material risks to sales and cost structures.
Margin Compression Factors Consolidated gross margin decreased one point to 66% due to inventory write-offs and severance costs related to workforce optimization initiatives.
International Operational Complexity Substantial international operations face ongoing risks from foreign currency fluctuations and navigating complex, evolving international legal compliance requirements.
Cybersecurity Threat Exposure Increasing frequency and sophistication of cybersecurity attacks pose risks to IT systems, potentially causing business disruption and reputational harm.

見通し

Expanding Myopia Management Market Focus remains on worldwide market penetration for recently introduced products, including the FDA-approved MiSight 1 day myopia management lenses.
CooperSurgical Strategic Expansion Continue strategic transactions to expand integrated solutions within fertility and women's health care areas, leveraging diversified product portfolio.
IT Control Weakness Remediated Material weakness in CooperSurgical IT general controls identified in 2024 has been fully remediated as of October 31, 2025, following enhancement efforts.
Increased R&D Investment R&D spending increased 11% overall, focused on new contact lens designs, manufacturing technology, and fertility device enhancements.

同業比較

売上高 (TTM)

Fresenius Medical Care AGFMS
$21.68B
+2.1%
Universal Health Services, Inc.UHS
$16.99B
+10.2%
Smith & Nephew plcSNN
$11.61B
+9.9%

粗利益率 (最新四半期)

Neurocrine Biosciences, Inc.NBIX
97.8%
-0.5pp
Universal Health Services, Inc.UHS
90.8%
+0.6pp
Doximity, Inc.DOCS
89.9%
+0.2pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
WST$18.02B36.717.4%0.0%
ILMN$17.85B21.033.7%44.6%
HOLX$16.75B31.011.0%27.5%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
3.4%
緩やかな成長
4四半期純利益CAGR
-6.7%
収益性の低下
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年3月5日
|
EPS:$1.03
|
売上高:$1.02B
財務レポート
財務データ
全年度
  • Form 10-K - FY 2025

    会計期末: 2025年10月31日|提出日: 2025年12月5日|
    売上高: $4.09B+5.1%
    |
    EPS: $1.88-4.6%
    予想を上回る
  • Form 10-Q - Q3 2025

    会計期末: 2025年7月31日|提出日: 2025年8月28日|
    売上高: $1.06B+5.7%
    |
    EPS: $0.49-7.5%
    予想を下回る
  • Form 10-Q - Q2 2025

    会計期末: 2025年4月30日|提出日: 2025年5月30日|
    売上高: $1.00B+6.3%
    |
    EPS: $0.44-2.5%
    予想を下回る
  • Form 10-Q - Q1 2025

    会計期末: 2025年1月31日|提出日: 2025年3月7日|
    売上高: $964.70M+3.6%
    |
    EPS: $0.52+26.8%
    予想を下回る
  • Form 10-K - FY 2024

    会計期末: 2024年10月31日|提出日: 2024年12月6日|
    売上高: $3.90B+8.4%
    |
    EPS: $1.97+32.2%
    予想を上回る
  • Form 10-Q - Q3 2024

    会計期末: 2024年7月31日|提出日: 2024年8月29日|
    売上高: $1.00B+7.8%
    |
    EPS: $0.53+23.3%
    予想を下回る
  • Form 10-Q - Q2 2024

    会計期末: 2024年4月30日|提出日: 2024年5月31日|
    売上高: $942.60M+7.4%
    |
    EPS: $0.45+125.0%
    予想を下回る
  • Form 10-Q - Q1 2024

    会計期末: 2024年1月31日|提出日: 2024年3月1日|
    売上高: $931.60M+8.5%
    |
    EPS: $0.41-4.7%
    予想を下回る